Macroaxis considers BioShares Biotechnology not too volatile given 1 month investment horizon. BioShares Biotechnology secures Sharpe Ratio (or Efficiency) of 0.29 which signifies that BioShares Biotechnology had 0.29% of return per unit of risk over the last 1 month. Our philosophy towards foreseeing volatility of a etf is to use all available market data together with company specific technical indicators that cannot be diversified away. We have found twenty-one technical indicators for BioShares Biotechnology Clinical Trials which you can use to evaluate future volatility of the entity. Please makes use of BioShares Biotechnology Downside Deviation of 1.86, Risk Adjusted Performance of 0.1341 and Mean Deviation of 1.26 to double-check if our risk estimates are consistent with your expectations.
|Time Horizon||30 Days Login to change|
BioShares Biotechnology Market Sensitivity
|As returns on market increase, returns on owning BioShares Biotechnology are expected to decrease by larger amounts. On the other hand, during market turmoil, BioShares Biotechnology is expected to significantly outperform it.One Month Beta |Analyze BioShares Biotechnology Demand TrendCheck current 30 days BioShares Biotechnology correlation with market (DOW)|
β = -2.3353
BioShares Biotechnology Technical Analysis
Projected Return Density Against MarketConsidering 30-days investment horizon, BioShares Biotechnology Clinical Trials has beta of -2.3353 . This suggests as returns on its benchmark rise, returns on holding BioShares Biotechnology Clinical Trials are expected to decrease by similarly larger amounts. On the other hand, during market turmoils, BioShares Biotechnology is expected to outperform its benchmark. In addition to that, BioShares Biotechnology Clinical Trials has an alpha of 1.0164 implying that it can potentially generate 1.0164% excess return over DOW after adjusting for the inherited market risk (beta).
Considering 30-days investment horizon, the coefficient of variation of BioShares Biotechnology is 344.87. The daily returns are destributed with a variance of 2.9 and standard deviation of 1.7. The mean deviation of BioShares Biotechnology Clinical Trials is currently at 1.31. For similar time horizon, the selected benchmark (DOW) has volatility of 0.39